Novo Nordisk (NVO) Stock May Be Below Fair Value After GLP 1 Legal News

Novo Nordisk stock has had a difficult three year stretch, yet current valuation checks suggest the market may now be pricing it more cautiously than its fundamentals imply. Recent returns have been weak, but the broader set of metrics points to a company that screens cheaper than many investors might assume.

• Over the past three years, Novo Nordisk shareholders have seen the stock fall about 49%, which means sentiment has already reset from earlier optimism.
• Growing demand for approved GLP 1 treatments such as Wegovy can support expectations for future cash flows, while legal and regulatory risks around obesity and diabetes drugs remain a key overhang for the whole sector.
• On Simply Wall St’s broader valuation checks, Novo Nordisk scores a 5 out of 6, which signals that the stock currently leans cheap on several key measures.

The issue now is whether Novo Nordisk’s recent share price and weak multi year returns already reflect the main risks, or if the stock still carries more downside than the valuation work implies.

Compare Novo Nordisk’s reset valuation with other beaten down yet financially solid stocks by scanning the hand picked 47 high quality undervalued stocks that share similar quality signals.

Is Novo Nordisk Still Cheap on Earnings?

P/E is a useful lens for Novo Nordisk because investors often focus on its earnings power from obesity and diabetes treatments. Right now, Novo Nordisk trades on a P/E of about 11.4x, which is below the wider pharmaceuticals industry average of 16.2x and well under the peer group average of 50.1x. That alone indicates the market is not assigning the same earnings multiple as it does to many other large drug makers.

The fair P/E ratio implied by the broader checks is 29.1x. This is much higher than the current 11.4x and indicates a sizeable discount on this metric. Despite Eli Lilly’s recent lawsuits around unapproved GLP 1 versions keeping attention on the sector, Novo Nordisk’s multiple still reflects a more cautious earnings valuation than the model or peers indicate.

On the P/E multiple, Novo Nordisk stock currently appears undervalued relative to both its fair ratio and sector benchmarks.

See what the numbers say about this price — find out in our valuation breakdown.

The Novo Nordisk Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the Novo Nordisk valuation puzzle leaves off. They spell out which assumptions about future growth, margins and earnings would need to hold for the stock to be worth meaningfully more or less than today’s price on the Community page. Each narrative ties a fair value estimate to a particular set of catalysts and risks for Novo Nordisk, so you can track over time which broad storyline is closest to reality.

One of the top community narratives on Novo Nordisk: 51% undervalued

"Current sentiment has swung deeply negative, but expectations are now low..."

Read one of the top narratives on Novo Nordisk

Do you think there's more to the story for Novo Nordisk? Head over to our Community to see what others are saying!

The Bottom Line

Novo Nordisk currently screens as undervalued on market multiples, with the broader checks pointing to a cautious earnings multiple relative to peers. That discount only helps if the business can sustain demand for its GLP 1 treatments while managing legal and regulatory pressures across obesity and diabetes drugs. For investors, the key question is whether the current gap between price and fundamentals reflects temporary pessimism or a justified warning on long term risk. The core of the bull versus bear debate is whether sentiment eventually improves enough for the P/E multiple to move closer to the levels applied to other large pharmaceutical stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com